Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RXC004 monotherapy in RNF43-positive advanced pancreatic ductal adenocarcinoma
ACTRN12624000588594Phase 2Terminated
- Sponsor
- Omico
- Start
- Dec 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zamaporvint in pancreatic adenocarcinoma (PDAC), sponsored by Omico. Primary endpoint: Progression-free survival rate. Started Dec 2025; status: terminated.
02
Drugs
zamaporvint
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ACTRN12624000588594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000588594.